Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Beam Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.02
0.02
51.8
60.9
378
63.5
140
Research and development
54.6
103
387
312
437
368
410
General and administrative
20.6
29.6
57.2
87.8
117
112
114
Operating expenses
75.2
133
444
399
554
479
523
Operating income
-75.2
-133
-392
-338
-176
-416
-384
Other non-operating income
-3.17
-61.8
21.8
78.3
45.3
38.9
304
Pre-tax income
-195
-371
-260
-131
-377
-80
Income tax
0
0
0
3.41
1.37
0.04
0
Net income
-78.3
-195
-371
-289
-133
-377
-80
EBITDA
-71.7
-128
-385
-324
-156
-394
-361
EPS, basic
-14.05
-4.19
-5.77
-4.13
-1.72
-4.58
-0.81
EPS, diluted
-14.05
-4.19
-5.77
-4.13
-1.72
-4.58
-0.81
Shares, basic (weighted)
6.48
46.7
64.2
70
77.2
82.3
98.9
Shares, diluted (weighted)
6.48
46.7
64.2
70
77.2
82.3
98.9
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
37.2
162
560
233
436
282
295
Short-term investments
138
845
754
569
950
Other current assets
2.7
8.65
7.36
14.8
21.2
27.4
23.5
Total current assets
94.5
308
1,273
1,093
1,211
878
1,269
Property, plant and equipment
24.3
38.5
84.3
116
125
111
105
Lease right-of-use assets
19
86.9
103
119
113
105
101
Long-term investments
2.58
Other non-current assets
4.98
3.14
1.72
1.93
2.15
1.25
0.63
Total assets
156
452
1,474
1,342
1,460
1,104
1,481
Accounts payable
7.85
6.31
7.47
9.03
1.62
3.87
10.2
Accrued liabilities
3.53
7.59
11.7
19.1
21.8
21.6
29.3
Deferred revenue
0.02
86.3
136
68.7
109
6.66
Total current liabilities
29.1
102
213
224
206
182
96.9
Lease liabilities
21.2
96
135
169
160
148
140
Other non-current liabilities
0.42
2.08
2.79
1.38
0.3
0.5
0.17
Total liabilities
55.2
206
648
608
478
370
243
Paid-in capital
1.85
643
1,594
1,793
2,170
2,299
2,877
Retained earnings
-203
-398
-768
-1,057
-1,190
-1,567
-1,641
Other comprehensive income
0.02
-0.01
-0.05
-2.43
0.6
0.68
1.11
Shareholders' equity
-201
246
827
733
981
734
1,238
Total equity
-201
246
827
733
981
734
1,238
Total liabilities and equity
156
452
1,474
1,342
1,460
1,104
1,481
Shares outstanding
7.33
57.3
68.4
71.3
81.6
83.6
102
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-78.3
-195
-371
-289
-133
-377
-80
Depreciation and amortization
3.5
4.74
7.45
14.1
20
21.9
22.3
Stock-based compensation
7.03
15.4
43.6
84.3
98.6
121
94.2
Change in payables
4.09
0.06
0.82
2.37
-7.58
1.81
6.04
Cash from operations
-72
-95.7
-66.3
22.5
-149
-347
-345
Capital expenditures
-12.5
-16.4
-46.8
-49
-33.7
-8.95
-14.9
Acquisitions
0
0
-0.08
Purchases of investments
-130
-282
-777
-1,617
-984
-486
-1,210
Sales and maturities of investments
76.1
199
529
1,205
1,090
680
842
Cash from investing
-66.7
-100
-294
-461
71.8
185
-121
Stock issued
0.19
3.16
757
108
237
5.6
4.77
Cash from financing
41.3
322
756
112
276
7.74
478
Net change in cash
-97.4
126
396
-327
199
-155
11.5
Free cash flow
-84.5
-112
-113
-26.4
-183
-356
-360
Interest paid
0.19
0.56
0.57
0.38
0.16
0.03
0
Income taxes paid
0.19
0.56
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $24.27 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-242.3%
Operating income / revenue.
EBITDA margin
-228.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-55.4%
Net income / revenue.
FCF margin
-238.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-230.3%
Cash from operations / revenue.
Return on equity (ROE)
-8.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-6.2%
Net income / average total assets.
Return on invested capital (ROIC)
-31.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
261.9%
Research and development expense / revenue.
Stock-based pay / revenue
52.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
8.6%
Capital expenditures / revenue.
D&A / revenue
14.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
120.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
31.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
466.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
68.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
19.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
38.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
34.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
3.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
26.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
20.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
12.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
16.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
14.6x
Current assets / current liabilities.
Quick ratio
14.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
14.3x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.09x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
7.2%
Total debt / total assets.
Liabilities / assets
23.0%
Total liabilities / total assets.
Net debt
-$1.05B
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.50
Revenue / diluted weighted shares.
FCF per share
-$3.57
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.44
Cash from operations / diluted weighted shares.
Book value per share
$10.34
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
16.1x
Market cap / revenue.
P/B
2.35x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.35x
Market cap / tangible book value, when positive.
EV/Sales
9.32x
Enterprise value / revenue.
FCF yield
-14.9%
Free cash flow / market cap.
Earnings yield
-3.5%
Net income / market cap (the inverse of P/E).
What was Beam Therapeutics Inc.'s revenue in fiscal 2025?
Beam Therapeutics Inc. reported revenue of $139.7M for fiscal 2025, 120% higher than the year before.
Was Beam Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $80.0M.
How much free cash flow did Beam Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $345.1M minus capital expenditures of $14.9M left free cash flow of -$360.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.